Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
BUSINESS
Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
Sumitomo Pharma on April 30 downwardly revised its consolidated financial projection for the fiscal year ended March 2024, shoving its projected deficit to higher levels as it expects to record large impairment losses and restructuring costs for a subsidiary. The…
To read the full story
Related Article
- Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
June 27, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
BUSINESS
- ALS Drug Radicava Now Available in Australia: Mitsubishi
May 28, 2025
- Lilly/NCNP Tie Up for Research on APOE Gene Testing
May 27, 2025
- Decline of Obesity Population Might Curb Rise in Healthcare Costs: Lilly
May 27, 2025
- Mitsubishi Tanabe Taps Moderna’s Nagayama as New EVP Post
May 27, 2025
- Moderna Launches Prefilled Version of Spikevax in Japan
May 27, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…